Greenwich LifeSciences (GLSI) Competitors $11.42 +0.03 (+0.26%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$11.56 +0.14 (+1.18%) As of 09/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLSI vs. OPT, ARVN, OLMA, KOD, ATYR, AQST, ESPR, IVA, RAPP, and CYRXShould you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Opthea (OPT), Arvinas (ARVN), Olema Pharmaceuticals (OLMA), Kodiak Sciences (KOD), aTyr Pharma (ATYR), Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry. Greenwich LifeSciences vs. Its Competitors Opthea Arvinas Olema Pharmaceuticals Kodiak Sciences aTyr Pharma Aquestive Therapeutics Esperion Therapeutics Inventiva Rapport Therapeutics CryoPort Greenwich LifeSciences (NASDAQ:GLSI) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation. Do analysts rate GLSI or OPT? Greenwich LifeSciences currently has a consensus target price of $42.00, indicating a potential upside of 267.78%. Opthea has a consensus target price of $1.33, indicating a potential downside of 60.90%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Greenwich LifeSciences is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Is GLSI or OPT more profitable? Opthea's return on equity of 0.00% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -700.90% -455.64% Opthea N/A N/A N/A Does the media refer more to GLSI or OPT? In the previous week, Greenwich LifeSciences had 8 more articles in the media than Opthea. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 1 mentions for Opthea. Opthea's average media sentiment score of 1.89 beat Greenwich LifeSciences' score of 0.35 indicating that Opthea is being referred to more favorably in the news media. Company Overall Sentiment Greenwich LifeSciences Neutral Opthea Very Positive Which has stronger valuation and earnings, GLSI or OPT? Greenwich LifeSciences has higher earnings, but lower revenue than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$15.79M-$1.36-8.40Opthea$30K19,437.00-$162.79MN/AN/A Do insiders and institutionals believe in GLSI or OPT? 4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 56.0% of Opthea shares are held by institutional investors. 51.7% of Greenwich LifeSciences shares are held by company insiders. Comparatively, 3.2% of Opthea shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, GLSI or OPT? Greenwich LifeSciences has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. SummaryGreenwich LifeSciences beats Opthea on 7 of the 13 factors compared between the two stocks. Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLSI vs. The Competition Export to ExcelMetricGreenwich LifeSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.25M$3.15B$5.78B$10.07BDividend YieldN/A2.32%5.69%4.62%P/E Ratio-8.4021.6075.2826.20Price / SalesN/A297.80474.0891.87Price / CashN/A45.3337.0859.91Price / Book60.119.7112.146.28Net Income-$15.79M-$53.33M$3.29B$270.85M7 Day Performance4.48%1.04%1.57%3.58%1 Month Performance-7.53%9.93%7.85%6.67%1 Year Performance-19.86%13.80%62.01%27.73% Greenwich LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLSIGreenwich LifeSciences1.5673 of 5 stars$11.42+0.3%$42.00+267.8%-18.2%$155.25MN/A-8.403Trending NewsOPTOpthea0.5328 of 5 stars$3.41+7.2%$1.33-60.9%+10.0%$583.10M$30K0.008Positive NewsGap UpHigh Trading VolumeARVNArvinas3.0414 of 5 stars$7.94+1.4%$19.76+148.9%-68.6%$574.86M$263.40M-7.86420Positive NewsOLMAOlema Pharmaceuticals2.8786 of 5 stars$7.58-8.8%$24.00+216.6%-35.2%$570.35MN/A-3.8370News CoveragePositive NewsAnalyst UpgradeKODKodiak Sciences3.611 of 5 stars$9.79-6.9%$11.75+20.0%+301.6%$555.68MN/A-2.5890ATYRaTyr Pharma2.6194 of 5 stars$5.46-2.7%$23.25+325.8%+178.3%$549.71M$230K-6.8253AQSTAquestive Therapeutics2.2485 of 5 stars$5.01-7.6%$10.29+105.3%+0.0%$540.50M$57.56M-7.16160ESPREsperion Therapeutics4.1364 of 5 stars$2.51-6.3%$7.00+178.9%+60.3%$540.35M$332.31M-5.12200Positive NewsIVAInventiva3.019 of 5 stars$5.37-3.6%$14.83+176.2%+157.6%$532.84M$9.95M0.00100Short Interest ↑Gap DownRAPPRapport Therapeutics2.7068 of 5 stars$31.47+119.2%$31.00-1.5%+22.7%$524.11MN/A-12.59N/ATrending NewsInsider TradeHigh Trading VolumeCYRXCryoPort3.7896 of 5 stars$10.04-3.0%$12.00+19.5%+21.6%$518.19M$228.38M7.551,186Positive News Related Companies and Tools Related Companies OPT Competitors ARVN Competitors OLMA Competitors KOD Competitors ATYR Competitors AQST Competitors ESPR Competitors IVA Competitors RAPP Competitors CYRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLSI) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
